A Single-arm, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine (Adenovirus Vector) for Inhalation in People 21 to 65 Years Old (Previously Primed With Authorized Vaccines)

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Recombinant-COVID-19-Vaccine-BravoVax (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors BravoVax

Most Recent Events

24 Apr 2023 Planned End Date changed from 1 Mar 2024 to 1 Jul 2024.
24 Apr 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Dec 2023.
24 Apr 2023 Planned initiation date changed from 1 Mar 2023 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight